423 related articles for article (PubMed ID: 28318643)
1. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
2. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
3. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
[TBL] [Abstract][Full Text] [Related]
4. The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
Leinster DA; Kulbe H; Everitt G; Thompson R; Perretti M; Gavins FN; Cooper D; Gould D; Ennis DP; Lockley M; McNeish IA; Nourshargh S; Balkwill FR
J Pathol; 2012 Jun; 227(2):136-45. PubMed ID: 22322968
[TBL] [Abstract][Full Text] [Related]
5. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
7. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
8. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
9. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
10. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.
Bapat J; Yamamoto TM; Woodruff ER; Qamar L; Mikeska RG; Aird KM; Watson ZL; Brubaker LW; Bitler BG
Cancer Gene Ther; 2024 Feb; 31(2):300-310. PubMed ID: 38030811
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
[TBL] [Abstract][Full Text] [Related]
12. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
13. STAT1-associated intratumoural T
Au KK; Le Page C; Ren R; Meunier L; Clément I; Tyrishkin K; Peterson N; Kendall-Dupont J; Childs T; Francis JA; Graham CH; Craig AW; Squire JA; Mes-Masson AM; Koti M
J Pathol Clin Res; 2016 Oct; 2(4):259-270. PubMed ID: 27917296
[TBL] [Abstract][Full Text] [Related]
14. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
15. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
[TBL] [Abstract][Full Text] [Related]
18. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
19. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
[TBL] [Abstract][Full Text] [Related]
20. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
